Have a feature idea you'd love to see implemented?
Let us know!
MIRM Mirum Pharmaceuticals Inc
Price (delayed)
$39.825
Market cap
$1.9B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.35
Enterprise value
$1.98B
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum's lead product candidate, maralixibat,
Highlights
The revenue has soared by 128% YoY and by 18% from the previous quarter
The company's gross profit has surged by 98% YoY and by 16% QoQ
Mirum Pharmaceuticals's equity has soared by 191% YoY but it has decreased by 2.4% from the previous quarter
The quick ratio has dropped by 52% year-on-year and by 11% since the previous quarter
The gross margin has declined by 13% year-on-year
Key stats
What are the main financial stats of MIRM
Market
Valuations
Earnings
Shares outstanding
47.71M
Market cap
$1.9B
Enterprise value
$1.98B
Price to earnings (P/E)
N/A
Price to book (P/B)
8.2
Price to sales (P/S)
7.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.5
Revenue
$264.38M
EBIT
-$93.15M
EBITDA
-$72.56M
Free cash flow
-$24.22M
Per share
Balance sheet
Liquidity
EPS
-$2.35
Free cash flow per share
-$0.51
Book value per share
$4.86
Revenue per share
$5.6
TBVPS
$8.45
Total assets
$660.75M
Total liabilities
$431.77M
Debt
$316.56M
Equity
$228.99M
Working capital
$255.52M
Debt to equity
1.38
Current ratio
3.28
Quick ratio
3.02
Net debt/EBITDA
-1.14
Margins
Efficiency
Dividend
EBITDA margin
-27.4%
Gross margin
72.3%
Net margin
-41.3%
Operating margin
-41%
Return on assets
-16.7%
Return on equity
-44.5%
Return on invested capital
-28.4%
Return on capital employed
-17%
Return on sales
-35.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MIRM stock price
How has the Mirum Pharmaceuticals stock price performed over time
Intraday
1.96%
1 week
3.66%
1 month
2.12%
1 year
46.15%
YTD
34.91%
QTD
2.12%
Financial performance
How have Mirum Pharmaceuticals's revenue and profit performed over time
Revenue
$264.38M
Gross profit
$191.07M
Operating income
-$108.43M
Net income
-$109.16M
Gross margin
72.3%
Net margin
-41.3%
The revenue has soared by 128% YoY and by 18% from the previous quarter
The company's gross profit has surged by 98% YoY and by 16% QoQ
The company's net margin has surged by 73% YoY and by 42% QoQ
The operating margin has soared by 60% YoY and by 15% from the previous quarter
Growth
What is Mirum Pharmaceuticals's growth rate over time
Valuation
What is Mirum Pharmaceuticals stock price valuation
P/E
N/A
P/B
8.2
P/S
7.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.5
The EPS has soared by 50% YoY and by 38% from the previous quarter
Mirum Pharmaceuticals's equity has soared by 191% YoY but it has decreased by 2.4% from the previous quarter
MIRM's price to book (P/B) is 46% higher than its 5-year quarterly average of 5.5 and 46% higher than its last 4 quarters average of 5.5
The revenue has soared by 128% YoY and by 18% from the previous quarter
MIRM's price to sales (P/S) is 4% higher than its last 4 quarters average of 6.7
Efficiency
How efficient is Mirum Pharmaceuticals business performance
The ROS has soared by 74% YoY and by 45% from the previous quarter
The ROE has soared by 66% YoY and by 42% QoQ
Mirum Pharmaceuticals's return on assets has surged by 65% YoY and by 37% QoQ
The ROIC has soared by 52% YoY and by 36% from the previous quarter
Dividends
What is MIRM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MIRM.
Financial health
How did Mirum Pharmaceuticals financials performed over time
MIRM's total assets is 53% higher than its total liabilities
The quick ratio has dropped by 52% year-on-year and by 11% since the previous quarter
The company's current ratio has shrunk by 50% YoY and by 11% QoQ
The company's debt is 38% higher than its equity
Mirum Pharmaceuticals's equity has soared by 191% YoY but it has decreased by 2.4% from the previous quarter
The debt to equity has plunged by 65% YoY but it has grown by 5% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.